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PCV65
PERSISTENCE WITH DIFFERENT FORMULATIONS OF THE
ANTIHYPERTENSIVE DRUG NIFEDIPINE
Breekveldt-Postma NS, Herings RMC
PHARMO Institute, Utrecht,The Netherlands
OBJECTIVES: To assess differences in persistent use of nifedip-
ine between the different formulations of nifedipine.
METHODS: Incident nifedipine users were selected in the period
of January, 1992 to December, 2001 from the PHARMO data-
base which includes linked drug-dispensing records and hospital
records of more than 1 million subjects in deﬁned areas in The
Netherlands. Patients with unaltered formulation and dosing 
frequency of nifedipine in the ﬁrst year of follow-up with at 
least two dispensings were included in the study. Episodes of
nifedipine use were constructed for each patient. The effect of
formulation on persistence of use in the ﬁrst episode with a
maximum of one year was assessed using Cox’s proportional
hazard analyses. Other determinants of persistent use that were
taken into account were hospitalization and co-medication
before and during nifedipine use. RESULTS: A total of 7902 inci-
dent users of nifedipine were included. One year persistence for
nifedipine varied between different formulations and increased
from 18% in patients using a non-retard formulation to 33% in
patients using retard formulations up to 45% in patients using
Adalat® OROS. The median length of the ﬁrst episode was 82
days for non-retard formulations, 148 days for retard formula-
tions and 285 days for Adalat® OROS. Multivariate analyses
including gender, age, co-medication and hospitalization showed
that patients using retard formulations were 1.4 times (RR: 1.42;
95%CI: 1.20–1.67) more persistent than patients using non-
retard nifedipine. Patients using Adalat® OROS were 1.8 times
(RR: 1.84; 95%CI: 1.54–2.20) more persistent than patients
using non-retard nifedipine. A separate analysis without non-
retard formulations showed that patients using Adalat® OROS
were 1.3 times (RR: 1.34; 95%CI: 1.23–1.46) more persistent
than patients using retard formulations. CONCLUSIONS:
Patients using once daily Adalat® OROS are more persistent
with nifedipine therapy than patients using twice daily retard 
formulations of nifedipine or trice daily nifedipine.
PCV66
POOLED EFFICACY OF DISEASE MANAGEMENT PROGRAMS
IN PATIENTS WITH CONGESTIVE HEART FAILURE—A
SYSTEMATIC REVIEW
Goehler A1, Dietz R1, Osterziel KJ1, Siebert U2
1Charitè Campus Virchow Klinikum, Berlin, Germany; 2Harvard
Medical School, Boston, MA, USA
OBJECTIVES: Hospital admission for CHF is an important
public health problem. Although several randomized controlled
trials (RCT) have successfully linked DMP’s to improved out-
comes and reduced readmission rates, most effects are statisti-
cally not signiﬁcant and vary regarding their magnitude. We
sought to 1) systematically combine the evidence on efﬁcacy of
disease management programs (DMP) in the treatment of con-
gestive heart failure (CHF); 2) identify reasons for the existing
heterogeneity; and 3) identify publication bias. METHODS: We
performed a systematic MEDLINE research on RCT’s investi-
gating DMP’s for CHF treatment from 1966-May, 2004. We
included all studies that were performed randomized, included
the core curriculum of a DMP (i.e., patient education, medica-
tion optimization, follow-up after discharge), and reported 
mortality and hospitalization as outcomes. We performed a meta-
analysis using random or ﬁxed effects models depending on 
the statistical heterogeneity of effects and estimated the pooled
relative risk (RR) with 95% conﬁdence intervals (95%CI). We
assessed effect heterogeneity using meta-regressions to identify
the impact of covariates on the DMP effect size. Publication bias
was assessed by inspection of funnel plots. RESULTS: Our analy-
sis included 16 studies from 5 different countries with data from
2868 patients. A random effects model which compared DMPs
vs. control groups yielded a pooled RR of 0.79 (95%CI
0.65–0.97) for mortality and of 0.87 (95%CI 0.79–0.95) for
rehospitalization during DMP. Meta-regression analysis identi-
ﬁed mean age, severity of disease (NYHA distribution), and dura-
tion of intervention as statistically signiﬁcant variables explaining
the heterogeneity. Funnel plot was asymmetric indicating a bias
towards positive studies. CONCLUSIONS: DMP’s in the CHF
treatment lead to a clinically relevant and statistically signiﬁcant
reduction of mortality and rehospitalization. Heterogeneity
across studies could largely be explained by age, severity of
disease, and duration of DMP. Our analysis may overestimate the
true DMP effect, because of a potential publication bias.
PCV67
USE OF CLOPIDOGREL AFTER ISCHEMIC VASCULAR EVENTS
IN THE THE NETHERLANDS
Goettsch WG1, Herings RMC2
1PHARMO Institute, Utrecht,The Netherlands; 2PHARMO Institute /
Utrecht Institute for Pharmaceutical Sciences, Utrecht University,
Utrecht,The Netherlands
OBJECTIVES: To assess the use of platelet aggregation
inhibitors in patients who were hospitalised for ischemic events
between 1998 and 2002. METHODS: Data were obtained from
the PHARMO database, which includes linked drug-dispensing
records and hospital records of more than 865,000 subjects in
deﬁned areas in The Netherlands. All patients hospitalised
between 1998 and 2002 for ischemic heart disease (IHD), cere-
brovascular disease (CVD), peripheral arterial disease (PAD) 
or having a percutaneous transluminal coronary angioplasty
(PTCA), were included in this retrospective population based
cohort study. The main outcome was the percentage of patients
using different types of platelet aggregation inhibitors speciﬁed
per indication within one month after discharge. RESULTS: In
total, 18,646 patients were included in this cohort. In 2002, 66%
of all patients with IHD, 61% of patients with CVD and 33%
of patients with PAD were treated with platelet inhibitors. More
than 80% of all patients with a ﬁrst admission for an acute
myocardial infarction or PTCA in 2002 were treated with
platelet aggregation inhibitors. Clopidogrel use (including com-
bined with aspirin) was most common in patients with IHD
(15% of all patients in 2002) and limited in patients with CVD
(5%) or PAD (2%). Clopidogrel (mainly in 2002) was almost
only combined with ASA in patients with IHD (11% of all
patients), especially in patients after PTCA (29%). CONCLU-
SIONS: There is still a considerable proportion of patients who
do not use antiplatelet therapy after ischemic events. Clopido-
grel use for secondary prevention in patients with ischemic 
vascular diseases seems to be rational given that guidelines rec-
ommend it for patients who can not be treated with aspirin.
Clopidogrel plus aspirin is mostly used in patients with IHD
treated with PTCA, suggesting that the current guidelines rec-
ommending this combination therapy in patients with acute
coronary syndrome and after PTCA, are increasingly applied.
PCV68
POPULATION IMPACT OF LOSARTAN USE ON STROKE 
IN FRANCE
Riou França L1, Souchet T2, Ragot S3, Herpin D4, Launois R1
1REES France, Paris, France; 2Merck Sharp & Dohme—Chibret, Paris,
France; 3Clinical Research Center, University Hospital, Poitiers, France;
4Department of Cardiology, University Hospital, Poitiers, France
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OBJECTIVES: In the LIFE study, losartan-based antihyperten-
sive therapy reduced the primary composite endpoint of cardio-
vascular death, myocardial infarction, or stroke by 13% (p =
0.02) and reduced the risk of stroke by 25% (p = 0.001), despite
comparable degree of blood pressure control in hypertensive
patients with left ventricular hypertension (LVH) over 5.5 years.
The objective of this study was to estimate LIFE target popula-
tion (55–80 years, Diastolic BP /Systolic BP: 95–115/ 160–200
mmHg, ECG-LVH without heart failure or angina pectoris) and
to project the reduction in stroke observed with losartan versus
atenolol-based therapy in the LIFE study in France. METHODS:
The population aged 55–80 was extracted from national statis-
tics. Prevalence of hypertension was estimated by extrapolating
the WHO MONICA data (Lille, Strasbourg, Toulouse) to this
segment of the population. The number of patients with con-
gestive heart failure and/or angina pectoris calculated from
Thales (computerized data base) was substracted. Prevalence of
LVH was based on the LIFE pilot study results. Number of
strokes averted was estimated by multiplying the number of
patients meeting LIFE inclusion criteria by the cumulative inci-
dence risk difference in stroke from LIFE at 5.5 years. RESULTS:
The French population aged 55–80 is comprised of 13 million
people. Half are hypertensive. We conservatively projected that
1.4 million individuals meet LIFE study criteria. Using losartan
based therapy in this target population, the projected cumulative
number of strokes over 5.5 years would be 67,957, compared to
90,147 with atenolol, a difference of stroke averted of 22,190.
CONCLUSIONS: The reduction with a losartan-based vs.
atenolol-based regimen should be viewed as representing an
incremental improvement relative to the beneﬁt of conventional
antihypertensives therapies, betablockers and diuretics. A popu-
lation wide prevention of using losartan in hypertensive patients
with LVH has the potential to have a major public health impact
by reducing stroke incidence in France.
PCV69
ATTITUDES OF OFFICE-BASED PHYSICIANS TOWARDS ANTI-
COAGULATION TREATMENT
Burkowitz J1, Raming B2, Brüggenjürgen B1
1Alpha Care GmbH, Celle, Germany; 2AstraZeneca GmbH, Wedel,
Germany
OBJECTIVES: Despite evidence-based guidelines the use of anti-
coagulation therapy in the prevention of strokes in patients with
nonvalvular atrial ﬁbrillation (AFib) is sub-optimal. The therapy
involves a trade-off between the potential beneﬁts of reducing
the risk of ischemic stroke versus the risk of haemorrhagic bleed-
ing. The aim of the study was to identify and describe physicians’
attitudes and beliefs in the assessment of risks connected with
anti-coagulation treatment. METHODS: A telephone interview
was conducted with a cross-section of GP’s, internists and car-
diologists randomly selected from a sub-set of 7,072 out of the
59,953 ofﬁce-based physicians of these specialities in Germany.
RESULTS: A total of 75 people completed the surveys (15.1%
of 498 eligible respondents). Only 25% of the physicians iden-
tiﬁed the right relative risk-reduction of anticoagulation (INR
2–3) while 52% of the physicians agreed strongly with the state-
ment that intracranial bleeding was more regrettable than
ischemic stroke. This was independent of former experiences
with bleeding complications. However, questioning physicians’
personal risk acceptance, most respondents would choose for
themselves a more effective therapy with higher risks (68%), like
anticoagulation therapy in case of AFib, accepting the risk of
bleeding (48%). Fear of bleeding complications was not inde-
pendent of questions of INR-control. Although 89.3% stressed
the high compliance which is needed for anticoagulation therapy,
only 13.4% of physicians disagreed strongly with the statement
that anticoagulation can be used without problems. CONCLU-
SIONS: Results show general acceptance of anticoagulation
treatment by German ofﬁce-based physicians. However, physi-
cians’ assessment of burden of therapy, like difﬁculty in INR-
control or need for patients’ compliance, leads to reservations
against anticoagulation. Also deﬁcits in knowledge of potential
beneﬁts of anticoagulation may contribute to sub-optimal usage
patterns.
PCV70
DECISION ANALYSIS AND COSTS OF LOW MOLECULAR
WEIGHT HEPARINS: A CASE STUDY IN FRANCE
Launois R, Gerlier L
REES France, Paris, France
OBJECTIVES: The aim of the study was to emphasize the neces-
sity of deﬁning the market when estimating the cost of two drugs.
One can appear cheaper than another when only a certain part
of the market is considered, and becoming the most expensive
after all societal costs have been taken into account. METHODS:
We focused on the sales of two widespread Low Molecular
Weight Heparins (LMWH) in France from an ambulatory point
of view. We then added the number of syringes distributed in
hospitals, and compared the new costs obtained. A decision tree
with market shares as probabilities made the calculation of
weighted mean costs particularly clear. RESULTS: When only
syringes sold by an ambulatory were considered, the daily cost
of enoxaparine preventive dosages was 31% more expensive
than that of tinzaparine (4.77€ vs. 3.63€). There was a 21% dif-
ference for curative dosages (13.18€ vs. 10.85€). When all the
sold syringes -hospital and open care- have been integrated in
the calculation of mean costs, the conclusion was completely
opposite: the daily cost for tinzaparine was 90% more expensive
than that of enoxaparine on preventive dosages (3.62€ vs.
1.91€). For curative dosages, tinzaparine daily cost reaches more
than twice the enoxaparine daily cost (10.09€ vs. 4.62€). Global
weighted daily costs of enoxaparine and tinzaparine regardless
of indication and market are respectively 2.18€ and 6.21€. CON-
CLUSIONS: The segmentation of the health care system and the
practice of different prices according to the type of markets
(ambulatory, hospital) prevent the public decision-makers to
have a clear view of the real cost of the drugs from a societal
viewpoint.
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EFFECT OF STATIN TITRATING ON CHOLESTEROL
REDUCTION AND GOAL ATTAINMENT IN ACTUAL CLINICAL
PRACTICE IN GERMANY
Rajagopalan S1,Alemao E2,Yin D2
1Consultant for Merck and Co, Whitehouse Station, NJ, USA; 2Merck
& Co, Whitehouse Station, NJ, USA
OBJECTIVES: To assess the effects of increasing the statin
potency in the management of hypercholesterolemia in general
practice and cardiology outpatient settings in Germany.
METHODS: A total of 603 randomly drawn patients from 
62 selected general and cardiology practices in Germany. All
patients had established coronary heart disease, initiated on
lipid-lowering therapy (LLT) between July 1, 1998 and June 30,
1999, had at least one LDL-C measurement in the preceding year
and were treated for secondary prevention for at least two years
(or until the patient’s death) after LLT initiation. Out of 603
patients, 153 had a ﬁnal switch to a higher potency statin (either
the same statin or a different one) and are analyzed here.
RESULTS: The 153 patients had a mean baseline LDL-C 
of 170.8mg/dL, mean age of 63 years, mean baseline TC of
